Clinical Trials

Clinical Trials



Fostamatinib - Immune Thrombocytopenic Purpura:

A Phase 3 program comprising two multi-center, randomized, double-blind, placebo-controlled clinical studies of fostamatinib disodium in the treatment of persistent/chronic immune thrombocytopenic purpura (ITP). The purpose of these studies is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic ITP. Rigel completed and reported results from the FIT Phase 3 clinical program of fostamatinib in ITP.

Phase 3 - ITP (047) Phase 3 - ITP (048)

Fostamatinib - AIHA

A Phase 2, open-label (active only), multi-center clinical study of fostamatinib disodium in the treatment of warm antibody autoimmune hemolytic anemia (AIHA). The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of AIHA.

Phase 2 - AIHA

Fostamatinib - IgA Nephropathy:

A Phase 2, multi-center, randomized, double-blind, ascending-dose, placebo-controlled clinical study of fostamatinib disodium in the treatment of IgA Nephropathy (IgAN). The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgAN.

Phase 2 - IgA Nephropathy